Management of Irritable Bowel Syndrome (IBS)

Initial Management: Diagnosis and Patient Education

• The American Gastroenterological Association recommends establishing a positive diagnosis without extensive testing in patients under 45 years meeting diagnostic criteria without alarm features, such as unintentional weight loss, blood in stool, fever, anemia, family history of colon cancer or inflammatory bowel disease 1, 2, 3
• Provide clear explanation that IBS is a disorder of gut-brain interaction with a benign but relapsing/remitting course to establish realistic expectations and reduce anxiety, as suggested by the National Institute of Diabetes and Digestive and Kidney Diseases 4, 1, 2

First-Line Treatment: Lifestyle Modifications (For All Patients)

• The American College of Gastroenterology recommends prescribing regular physical activity to all IBS patients, as exercise provides significant benefits for symptom management 1, 2, 3
• Establish regular time for defecation and ensure adequate sleep hygiene, as recommended by the American Gastroenterological Association 2

Dietary Interventions: Stepwise Approach

For Constipation-Predominant IBS (IBS-C)

• The National Institute of Diabetes and Digestive and Kidney Diseases recommends starting with soluble fiber supplementation (ispaghula/psyllium) at 3-4 g/day and gradually increasing to avoid bloating 4, 1, 3
• Avoid insoluble fiber (wheat bran) as it worsens symptoms, particularly bloating, as suggested by the American Gastroenterological Association 4, 2

For Diarrhea-Predominant IBS (IBS-D)

• The American College of Gastroenterology recommends reducing fiber intake and identifying excessive consumption of lactose, fructose, sorbitol, caffeine, or alcohol 5, 1
• Patients consuming substantial lactose (>280 ml milk/day) may benefit from lactose exclusion, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 5

For Refractory Symptoms

• The American Gastroenterological Association recommends considering a supervised trial of low FODMAP diet delivered in three phases: restriction, reintroduction, and personalization 4, 1
• A gluten-free diet is not recommended in IBS, as stated by the National Institute of Diabetes and Digestive and Kidney Diseases 4

Pharmacological Treatment: Symptom-Targeted Approach

For Abdominal Pain and Cramping

• The American College of Gastroenterology recommends using antispasmodics with anticholinergic properties (dicyclomine) as first-line therapy for abdominal pain, particularly when symptoms are meal-related 4, 1, 2
• Peppermint oil may be useful as an alternative antispasmodic, though evidence is more limited, as suggested by the National Institute of Diabetes and Digestive and Kidney Diseases 5, 1, 3

For Diarrhea-Predominant IBS (IBS-D)

• The American Gastroenterological Association recommends prescribing loperamide 4-12 mg daily either regularly or prophylactically (before going out) to reduce stool frequency, urgency, and fecal soiling 4, 1, 2, 3
• Titrate the dose carefully as abdominal pain, bloating, nausea, and constipation are common and may limit tolerability, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 4

For Mixed IBS or Refractory Pain

• The American College of Gastroenterology recommends tricyclic antidepressants (TCAs) as the most effective first-line pharmacological treatment for mixed symptoms and refractory pain 4, 1, 2
• Start with amitriptyline 10 mg once daily and titrate slowly to a maximum of 30-50 mg once daily, as suggested by the National Institute of Diabetes and Digestive and Kidney Diseases 4, 1, 2

Advanced Pharmacological Options (Secondary Care)

• The American Gastroenterological Association recommends 5-HT3 receptor antagonists (ondansetron 4 mg once daily titrated to maximum 8 mg three times daily) for IBS-D refractory to loperamide and TCAs, though constipation is the most common side effect 4
• Eluxadoline is efficacious but contraindicated in patients with prior sphincter of Oddi problems, cholecystectomy, alcohol dependence, pancreatitis, or severe liver impairment, as stated by the National Institute of Diabetes and Digestive and Kidney Diseases 4

Psychological Therapies: For Refractory Cases

• The American Psychological Association recommends considering IBS-specific cognitive behavioral therapy or gut-directed hypnotherapy when symptoms persist despite pharmacological treatment for 12 months 5, 4, 1, 2, 3
• These brain-gut behavior therapies are specifically designed for IBS and differ from psychological therapies that target depression and anxiety alone, as suggested by the American Gastroenterological Association 1

Multidisciplinary Care Coordination

• The American Gastroenterological Association recommends referring to a gastroenterology dietitian if the patient consumes considerable intake of foods that trigger IBS symptoms, shows dietary deficits or nutritional deficiency, shows recent unintended weight loss, or requests dietary modification advice 2
• Refer to a gastropsychologist if IBS symptoms or their impact are moderate to severe, the patient accepts that symptoms are related to gut-brain dysregulation, and has time to devote to learning new coping strategies, as recommended by the American Psychological Association 1, 2

Treatment Monitoring and Adjustment

• The American College of Gastroenterology recommends reviewing treatment efficacy after 3 months and discontinuing ineffective medications 1, 2
• Recognize that symptoms may relapse and remit over time, requiring periodic adjustment of treatment strategy, as suggested by the National Institute of Diabetes and Digestive and Kidney Diseases 1, 2

Evidence‑Based Pharmacologic Management of IBS‑C

First‑Line Pharmacologic Therapy

• Linaclotide 290 µg taken once daily is recommended as the first‑line agent for IBS‑C because high‑quality evidence from two large randomized controlled trials demonstrates a modest but statistically significant improvement in both abdominal pain and the frequency of complete spontaneous bowel movements (combined responder rate ≈ 12‑13 % vs 3‑5 % with placebo). 6
• Diarrhea is an adverse effect that can lead to discontinuation in a small proportion of patients; clinicians should counsel patients about this risk before initiating therapy. 6

Second‑Line Pharmacologic Therapy

• Lubiprostone is advised as a second‑line option when linaclotide is ineffective, not tolerated, or unaffordable; two 12‑week randomized controlled trials reported a small but measurable improvement in global IBS‑C symptoms, with a moderate quality of evidence. 6

Management of Predominant Abdominal Pain

• Tricyclic antidepressants (e.g., amitriptyline, initiated at low dose and titrated up to 30‑50 mg daily) can be used for refractory abdominal pain, providing modest relief of global symptoms and pain; the supporting evidence is of low quality, and clinicians should monitor for QT‑interval prolongation. [7][8]
• Selective serotonin reuptake inhibitors (SSRIs) are not recommended for IBS‑C unless a co‑existing mood disorder is present, as pooled data from five randomized trials showed no benefit for global relief or abdominal pain. [7][8]

Agents Not Recommended as Primary Therapy for IBS‑C

• Osmotic laxatives (e.g., polyethylene glycol) and stimulant laxatives (e.g., senna) should not be used as primary treatments for IBS‑C because evidence supporting their efficacy specifically in IBS‑C is very limited, despite proven effectiveness for chronic idiopathic constipation. 9

Diagnosis and Initial Management of IBS‑C

Diagnostic Criteria and Testing

• Use Rome IV criteria (abdominal pain ≥ 1 day/week for ≥ 3 months with defecation changes) to diagnose IBS‑C in adults < 45 years without alarm features, avoiding extensive testing. 10
• Recognize IBS‑C as a gut‑brain interaction disorder with a benign, relapsing‑remitting course; while cure is unlikely, substantial improvement in symptoms and quality of life is achievable. 11
• Do not perform colonoscopy in patients < 45 years without alarm features, as it provides no additional benefit and may increase anxiety. 11

Lifestyle and Dietary Interventions

• Recommend regular physical activity as a foundational therapy because exercise significantly improves constipation and overall IBS‑C symptoms. 11
• Initiate soluble fiber (psyllium) at 3–4 g/day, titrating upward to minimize bloating; this regimen improves global IBS‑C symptoms and abdominal pain. 11
• Consider peppermint oil as an alternative antispasmodic for meal‑related abdominal pain; evidence is modest but supportive. 11

Refractory Symptom Management

• For patients with persistent symptoms despite first‑line measures, implement a supervised low‑FODMAP diet in three phases (restriction, reintroduction, personalization) under dietitian guidance to optimize efficacy and prevent nutritional deficits. 12
• Refer patients with refractory IBS‑C after ≥ 12 months of standard therapy to IBS‑specific cognitive‑behavioral therapy or gut‑directed hypnotherapy, which are designed to address brain‑gut dysregulation. [12] [11]

Multidisciplinary Care and Referral

• Establish multidisciplinary collaboration with gastroenterology dietitians and gastropsychologists to deliver comprehensive IBS‑C care. 12
• Refer to a dietitian when the patient consumes large amounts of IBS‑trigger foods, exhibits dietary deficiencies, experiences unintended weight loss, or requests dietary counseling. 12
• Refer to a gastropsychologist when IBS‑C symptoms are moderate to severe, the patient acknowledges gut‑brain involvement, and has capacity to engage in coping‑skill training. 12

Clinical Pitfalls and Decision‑Making

• Avoid extensive diagnostic testing after IBS‑C diagnosis is confirmed in patients < 45 years without alarm features, as further testing offers no clinical advantage. 11
• Do not use low‑dose tricyclic antidepressants solely for co‑existing psychological symptoms; if a mood disorder is present, prescribe an SSRI instead. 12
• Engage in shared decision‑making with patients when selecting therapies, considering preferences, out‑of‑pocket costs, and insurance coverage. [10] [13]